Buy Rating Affirmed for Annovis Bio Amidst Promising Drug Developments and Strategic Team Expansion
Annovis Bio Analyst Ratings
Buy Rating Affirmed: Promising Buntanetap Phase 3 Results and Increased Approval Probability Boost Annovis Bio's Price Target
Annovis Bio Analyst Ratings
Maxim Group Sticks to Its Hold Rating for Annovis Bio (ANVS)
Annovis Bio Analyst Ratings
Rodman & Renshaw Reiterates Buy on Annovis Bio, Maintains $67 Price Target
Annovis Bio Analyst Ratings
Annovis Bio Analyst Ratings
Buy Rating Maintained for Annovis Bio Ahead of Key Parkinson's Drug Trial Results
Annovis Bio Analyst Ratings
Buy Rating Reaffirmed for Annovis Bio Amid Positive Prospects for Parkinson's Treatment
Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)
Annovis Bio Analyst Ratings
Annovis Bio Analyst Ratings
Buy Rating Reiterated for Annovis Bio Amid Anticipated Positive Trial Results for Alzheimer's and Parkinson's Treatments
Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbSci (ABSI)
Analysts Are Bullish on These Healthcare Stocks: Insulet (PODD), Annovis Bio (ANVS)
Annovis Bio Analyst Ratings
Annovis Bio Stock Downgraded to Hold With $9 Price Target